Transrectal ultrasound microbubble contrast angiography of the prostate. Ragde, H., Kenny, G. M., Murphy, G. P., & Landin, K. Prostate, 32(4):279--283, September, 1997.
abstract   bibtex   
BACKGROUND: Prostate cancer, suspected by serum prostate-specific antigen (PSA) elevation and/or digital abnormalities, is not always evident on gray-scale or color Doppler transrectal ultrasound (TRUS). EchoGen (Sonus Pharmaceuticals, Inc., Bothell, WA), a blood vessel image enhancer able to visualize smaller, low-flow vessels and thus possibly the microvascular angiogenesis often associated with cancer, was employed to see if it would improve prostate cancer detection, particularly in patients with a rising serum PSA and prior negative biopsies. METHODS: Color Doppler TRUS was performed before and after intravenous injection of 0.05 ml/kg of EchoGen. Random and/or specifically directed sextant TRUS biopsies were performed. RESULTS: Fifteen patients with serum PSA elevations were included in the study. Fourteen had a negative prior biopsy (1-3 x). Prostate cancer was detected in 5 patients. Microvascular patterns were judged abnormal in 8 patients, 2 of which proved malignant, 2 of which were benign, and 1 of which was diagnosed with prostatis. False-negative results were observed in 3 patients, whose positive biopsy sites were from the prostate apex. CONCLUSIONS: Following EchoGen administration, prostate blood vessel image enhancement was noted in all patients, and there were no adverse reactions during or after EchoGen administration with the dose employed.
@article{ragde_transrectal_1997,
	title = {Transrectal ultrasound microbubble contrast angiography of the prostate.},
	volume = {32},
	abstract = {BACKGROUND: Prostate cancer, suspected by serum prostate-specific antigen (PSA) elevation and/or digital abnormalities, is not always evident on gray-scale or color Doppler transrectal ultrasound (TRUS). EchoGen (Sonus Pharmaceuticals, Inc., Bothell, WA), a blood vessel image enhancer able to visualize smaller, low-flow vessels and thus possibly the microvascular angiogenesis often associated with cancer, was employed to see if it would improve prostate cancer detection, particularly in patients with a rising serum PSA and prior negative biopsies. METHODS: Color Doppler TRUS was performed before and after intravenous injection of 0.05 ml/kg of EchoGen. Random and/or specifically directed sextant TRUS biopsies were performed. RESULTS: Fifteen patients with serum PSA elevations were included in the study. Fourteen had a negative prior biopsy (1-3 x). Prostate cancer was detected in 5 patients. Microvascular patterns were judged abnormal in 8 patients, 2 of which proved malignant, 2 of which were benign, and 1 of which was diagnosed with prostatis. False-negative results were observed in 3 patients, whose positive biopsy sites were from the prostate apex. CONCLUSIONS: Following EchoGen administration, prostate blood vessel image enhancement was noted in all patients, and there were no adverse reactions during or after EchoGen administration with the dose employed.},
	language = {eng},
	number = {4},
	journal = {Prostate},
	author = {Ragde, H. and Kenny, G. M. and Murphy, G. P. and Landin, K.},
	month = sep,
	year = {1997},
	keywords = {Aged, Aged; Biopsy; Contrast Media; Diagnosis, Biopsy, Color, Contrast Media, Diagnosis, Differential, Differential; False Negative Reactions; Humans; Male; Microcirculation, Doppler, False Negative Reactions, Humans, Microcirculation, Middle Aged, Neovascularization, Pathologic, Pathologic; Prostate, Prostate-Specific Antigen, Prostatic Hyperplasia, Prostatic Neoplasms, Ultrasonography, blood, blood supply/ultrasonography, blood supply/ultrasonography; Prostate-Specific Antigen, blood; Prostatic Hyperplasia, male, pathology/ultrasonography, pathology/ultrasonography; Middle Aged; Neovascularization, pathology/ultrasonography; Prostatic Neoplasms, pathology/ultrasonography; Ultrasonography, prostate},
	pages = {279--283}
}

Downloads: 0